John Parkinson

This designation of the company’s respiratory syncytial virus (RSV) vaccine candidate, PF-06928316, will help to expedite its development and review.

Along with reporting positive data in the youngest pediatric population, the company is working with the Food and Drug Administration (FDA) for emergency use authorization of its vaccine in children 6 years to under 11 years as well as the 12-17 age groups.

A new virtual program aims to train clinicians and other providers on terminology and how to engage patients in effective dialogue and counseling.

The submission is for a fourth dose of its Spikevax (mRNA-1273) vaccine in adults 18 years of age and older.

The application is based on 2 Israeli studies for the additional shot for people 65 years and older.

This study comes just weeks after the company announced another HIV vaccine trial.

In a nationally televised interview, Pfizer Albert Bourla said it is necessary to fend off waning protection.

The phase 3 results for its antibiotic, cefepime-taniborbactam, demonstrated it met its primary endpoint and the company says it is on track for a fourth quarter 2022 FDA NDA.

The company is examining its antiviral pill for children 6 to 17 years of age in combating COVID-19.

The company’s investigational PF-06425090 vaccine did show benefits including decreased median infection period and no hospitalizations in the vaccinated cohort.

This week, one of the m-RNA COVID-19 vaccine’s effectiveness was shown to drop from 68% to 12% in children 5-11 years old within a month. This data raises concerns of what should be done to protect this pediatric population.

The federal agency cited chemistry manufacturing and controls issues with vials.

New research points to vaccine effectiveness against infection dropping from 68% to 12% in this pediatric population within a month.

Although it is possible, a small Danish study showed the majority of these cases were often mild and in unvaccinated individuals.

This is broken down into counties that are either high, medium, or low level categories. Many areas of the US are able to go without masks.

The federal agency is going to lay out recommendations for states.

This is the first authorized COVID-19 vaccine that was developed by a Canadian-based company, and the first that used a plant-based protein technology.

Pfizer’s TicoVac vaccine was developed to immunize young children and adults to prevent Tick-Borne Encephalitis.

The companies plan to seek regulatory authorization for the vaccine both in the US and Europe.

A clinician offers his perspective on how the virus is behaving and the role that vaccines and therapies will play.

A preprint study shows the variant is resistant to some monoclonal antibodies and vaccines.

Investigators looked at myocardial infarction risks over several years within 2 health care systems examining both people with HIV (PWH) and people without HIV (PWoH).

The investigational therapy has demonstrated promising results utilizing subcutaneous injections every 6 months.

For people living with HIV (PLWH) an accelerated aging process may affect the severity of their disease.

Investigators looked at full vaccination and booster dose observational data to offer some insights on protection and breakthrough infections.

This patient is the first mixed race woman to experience HIV-1 remission, and potentially opens up the door to others being treated with a novel treatment.

Investigators found a couple of different factors for this phenomenon.

Data shown in the Pinetree clinical trial and being presented with 2 posters at CROI demonstrate both benefits and safety in preventing progression to more severe disease.

Investigators looked to see if this population might be candidates for this form of HIV prevention.

Boston’s Fenway Health looked at testing and prevention trends during 3 phases of the COVID-19 pandemic.